ELAC2

ElaC ribonuclease Z 2
Identifiers
Symbols ELAC2 ; COXPD17; ELC2; HPC2
External IDs OMIM: 605367 MGI: 1890496 HomoloGene: 6403 GeneCards: ELAC2 Gene
EC number 3.1.26.11
RNA expression pattern
More reference expression data
Orthologs
Species Human Mouse
Entrez 60528 68626
Ensembl ENSG00000006744 ENSMUSG00000020549
UniProt Q9BQ52 Q80Y81
RefSeq (mRNA) NM_001165962 NM_023479
RefSeq (protein) NP_001159434 NP_075968
Location (UCSC) Chr 17:
12.99 – 13.02 Mb		 Chr 11:
64.98 – 65 Mb
PubMed search

Zinc phosphodiesterase ELAC protein 2 is an enzyme that in humans is encoded by the ELAC2 gene.[1][2][3] on chromosome 17. It is an endonuclease thought to be involved in mitochondrial tRNA maturation,

Function

The ELAC2 gene encodes a protein that is 92 kDa in size and is localized to the mitochondrion [4] and the nucleus. The ELAC2 protein is a zinc phosphodiesterase, which is known to show tRNA 3'-processing endonuclease activity inside the mitochondria. Mitochondria contain their own pool of tRNAs that are involved in the protein translation of 13 subunits of the respiratory chain that are encoded by the mitochondrial genome. ELAC2 functions in the maturation of tRNA by removing a 3'-trailer (extra 3' nucleotides) from tRNA precursors, generating 3' termini of tRNAs.

The reaction leaves a 3'-hydroxy group is left at the tRNA end, and a 5'-phosphoryl group at the cleaved, trailing end. The reaction requires zinc ions as co-factors.

Clinical significance

Variants of the ELAC2 gene are associated with prostate cancer, hereditary 2 (HPC2), a condition associated with familial cancer of the prostate.[5][6] Multiple mutations including truncation and missense mutations are known to cause the disease from multiple families based on linkage analysis and positional cloning.[6]

In addition, mutations in ELAC2 are known to cause combined oxidative phosphorylation deficiency 17 (COXPD17), a rare autosomal recessive disorder of mitochondrial functions characterized by severe hypertrophic cardiomyopathy.[7]

References

  1. ↑ Rebbeck TR, Walker AH, Zeigler-Johnson C, Weisburg S, Martin AM, Nathanson KL, Wein AJ, Malkowicz SB (Oct 2000). "Association of HPC2/ELAC2 Genotypes and Prostate Cancer". Am J Hum Genet 67 (4): 1014–9. doi:10.1086/303096. PMC: 1287872. PMID 10986046.
  2. ↑ Noda D, Itoh S, Watanabe Y, Inamitsu M, Dennler S, Itoh F, Koike S, Danielpour D, ten Dijke P, Kato M (September 2006). "ELAC2, a putative prostate cancer susceptibility gene product, potentiates TGF-beta/Smad-induced growth arrest of prostate cells". Oncogene 25 (41): 5591–600. doi:10.1038/sj.onc.1209571. PMID 16636667.
  3. ↑ "Entrez Gene: ELAC2 elaC homolog 2 (E. coli)".
  4. ↑ Brzezniak LK, Bijata M, Szczesny RJ, Stepien PP (2011). "Involvement of human ELAC2 gene product in 3' end processing of mitochondrial tRNAs". RNA Biol 8 (4): 616–26. doi:10.4161/rna.8.4.15393. PMID 21593607.
  5. ↑ Wang L, McDonnell SK, Elkins DA, Slager SL, Christensen E, Marks AF, Cunningham JM, Peterson BJ, Jacobsen SJ, Cerhan JR, Blute ML, Schaid DJ, Thibodeau SN (2001). "Role of HPC2/ELAC2 in hereditary prostate cancer". Cancer Res. 61 (17): 6494–9. PMID 11522646.
  6. 1 2 Rökman A, Ikonen T, Mononen N, Autio V, Matikainen MP, Koivisto PA, Tammela TL, Kallioniemi OP, Schleutker J (2001). "ELAC2/HPC2 involvement in hereditary and sporadic prostate cancer". Cancer Res. 61 (16): 6038–41. PMID 11507049.
  7. ↑ Haack TB, Kopajtich R, Freisinger P, Wieland T, Rorbach J, Nicholls TJ, Baruffini E, Walther A, Danhauser K, Zimmermann FA, Husain RA, Schum J, Mundy H, Ferrero I, Strom TM, Meitinger T, Taylor RW, Minczuk M, Mayr JA, Prokisch H (2013). "ELAC2 mutations cause a mitochondrial RNA processing defect associated with hypertrophic cardiomyopathy". Am. J. Hum. Genet. 93 (2): 211–23. doi:10.1016/j.ajhg.2013.06.006. PMC: 3738821. PMID 23849775.

Further reading

  • Bonaldo MF, Lennon G, Soares MB (1997). "Normalization and subtraction: two approaches to facilitate gene discovery". Genome Res. 6 (9): 791–806. doi:10.1101/gr.6.9.791. PMID 8889548. 
  • Satijn DP, Gunster MJ, van der Vlag J; et al. (1997). "RING1 is associated with the polycomb group protein complex and acts as a transcriptional repressor". Mol. Cell. Biol. 17 (7): 4105–13. PMC: 232264. PMID 9199346. 
  • Sewalt RG, Gunster MJ, van der Vlag J; et al. (1999). "C-Terminal Binding Protein Is a Transcriptional Repressor That Interacts with a Specific Class of Vertebrate Polycomb Proteins". Mol. Cell. Biol. 19 (1): 777–87. PMC: 83934. PMID 9858600. 
  • Tavtigian SV, Simard J, Teng DH; et al. (2001). "A candidate prostate cancer susceptibility gene at chromosome 17p". Nat. Genet. 27 (2): 172–80. doi:10.1038/84808. PMID 11175785. 
  • Xu J, Zheng SL, Carpten JD; et al. (2001). "Evaluation of Linkage and Association of HPC2/ELAC2 in Patients with Familial or Sporadic Prostate Cancer". Am. J. Hum. Genet. 68 (4): 901–11. doi:10.1086/319513. PMC: 1275644. PMID 11254448. 
  • Rökman A, Ikonen T, Mononen N; et al. (2001). "ELAC2/HPC2 involvement in hereditary and sporadic prostate cancer". Cancer Res. 61 (16): 6038–41. PMID 11507049. 
  • Wang L, McDonnell SK, Elkins DA; et al. (2001). "Role of HPC2/ELAC2 in hereditary prostate cancer". Cancer Res. 61 (17): 6494–9. PMID 11522646. 
  • Shea PR, Ferrell RE, Patrick AL; et al. (2002). "ELAC2 and prostate cancer risk in Afro-Caribbeans of Tobago". Hum. Genet. 111 (4–5): 398–400. doi:10.1007/s00439-002-0816-1. PMID 12384782. 
  • Strausberg RL, Feingold EA, Grouse LH; et al. (2003). "Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences". Proc. Natl. Acad. Sci. U.S.A. 99 (26): 16899–903. doi:10.1073/pnas.242603899. PMC: 139241. PMID 12477932. 
  • Camp NJ, Tavtigian SV (2003). "Meta-Analysis of Associations of the Ser217Leu and Ala541Thr Variants in ELAC2 (HPC2) and Prostate Cancer". Am. J. Hum. Genet. 71 (6): 1475–8. doi:10.1086/344516. PMC: 378598. PMID 12515253. 
  • Fujiwara H, Emi M, Nagai H; et al. (2003). "Association of common missense changes in ELAC2 ( HPC2) with prostate cancer in a Japanese case-control series". J. Hum. Genet. 47 (12): 641–8. doi:10.1007/s100380200099. PMID 12522685. 
  • Korver W, Guevara C, Chen Y; et al. (2003). "The product of the candidate prostate cancer susceptibility gene ELAC2 interacts with the gamma-tubulin complex". Int. J. Cancer 104 (3): 283–8. doi:10.1002/ijc.10945. PMID 12569551. 
  • Shi Y, Sawada J, Sui G; et al. (2003). "Coordinated histone modifications mediated by a CtBP co-repressor complex". Nature 422 (6933): 735–8. doi:10.1038/nature01550. PMID 12700765. 
  • Takaku H, Minagawa A, Takagi M, Nashimoto M (2003). "A candidate prostate cancer susceptibility gene encodes tRNA 3′ processing endoribonuclease". Nucleic Acids Res. 31 (9): 2272–8. doi:10.1093/nar/gkg337. PMC: 154223. PMID 12711671. 
  • Severi G, Giles GG, Southey MC; et al. (2003). "ELAC2/HPC2 polymorphisms, prostate-specific antigen levels, and prostate cancer". J. Natl. Cancer Inst. 95 (11): 818–24. doi:10.1093/jnci/95.11.818. PMID 12783937. 
  • Takahashi H, Lu W, Watanabe M; et al. (2003). "Ser217Leu polymorphism of the HPC2/ELAC2 gene associated with prostatic cancer risk in Japanese men". Int. J. Cancer 107 (2): 224–8. doi:10.1002/ijc.11347. PMID 12949798. 
  • Stanford JL, Sabacan LP, Noonan EA; et al. (2003). "Association of HPC2/ELAC2 polymorphisms with risk of prostate cancer in a population-based study". Cancer Epidemiol. Biomarkers Prev. 12 (9): 876–81. PMID 14504198. 
  • Adler D, Kanji N, Trpkov K; et al. (2004). "HPC2/ELAC2 gene variants associated with incident prostate cancer". J. Hum. Genet. 48 (12): 634–8. doi:10.1007/s10038-003-0091-6. PMID 14625808. 
  • Ota T, Suzuki Y, Nishikawa T; et al. (2004). "Complete sequencing and characterization of 21,243 full-length human cDNAs". Nat. Genet. 36 (1): 40–5. doi:10.1038/ng1285. PMID 14702039. 


This article is issued from Wikipedia - version of the Saturday, April 16, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.